Skip to main content

Table 2 Evaluation of the markers using the validation set with 16 non-lepidic AD and 11 PDSCC patients

From: Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung

AD markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) AD SCC AD SCC (95 % CI†) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
ST6GALNAC1* 15 0 1 11 0.938
(0.698–0.998)
1.000
(0.715–1.000)
1.000
(0.782–1.000)
0.917
(0.615–0.998)
0.963
(0.810–0.999)
TTF-1 10 0 6 11 0.625
(0.354–0.848)
1.000
(0.715–1.000)
1.000
(0.692–1.000)
0.647
(0.383–0.858)
0.778
(0.577–0.914)
napsin A 12 0 4 11 0.750
(0.476–0.927)
1.000
(0.715–1.000)
1.000
(0.735–1.000)
0.733
(0.449–0.922)
0.852
(0.663–0.958)
SCC markers (Marker status) (+) (−) Sensitivity Specificity PPV NPV Accuracy
(subtype) SCC AD SCC AD (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
SPATS2* 7 0 4 16 0.636
(0.308–0.891)
1.000
(0.794–1.000)
1.000
(0.590–1.000)
0.800
(0.563–0.943)
0.852
(0.663–0.958)
CK5 7 0 4 16 0.636
(0.308–0.891)
1.000
(0.794–1.000)
1.000
(0.590–1.000)
0.800
(0.563–0.943)
0.852
(0.663–0.958)
DSG3 6 0 5 16 0.545
(0.234–0.833)
1.000
(0.794–1.000)
1.000
(0.541–1.000)
0.762
(0.528–0.918)
0.815
(0.619–0.937)
p40 7 0 4 16 0.636
(0.308–0.891)
1.000
(0.794–1.000)
1.000
(0.590–1.000)
0.800
(0.563–0.943)
0.852
(0.663–0.958)
CK6 5 9 6 7 0.455
(0.167–0.766)
0.438
(0.198–0.701)
0.357
(0.128–0.649)
0.538
(0.251–0.808)
0.444
(0.255–0.647)
  1. PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval
  2. †: 95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
  3. * Novel biomarkers identified in the present study